Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16980934 | 0.84 | NOS1 (0.39) | NOS1DHFR | |
| SCHEMBL8813993 | 0.81 | NOS1 (0.61) | NOS1DHFR | |
| SCHEMBL13019221 | 0.81 | DHFR (0.56) | NOS1DHFR | |
| SCHEMBL14435374 | 0.80 | NOS1 (0.55) | NOS1DHFR | |
| SCHEMBL30432658 | 0.80 | NOS1 (0.55) | NOS1DHFR | |
| SCHEMBL20780857 | 0.79 | NOS1 (0.67) | NOS1DHFR | |
| SCHEMBL26500537 | 0.79 | NOS1 (0.62) | NOS1DHFR | |
| SCHEMBL10615664 | 0.79 | NOS1 (0.62) | NOS1DHFR | |
| SCHEMBL64146 | 0.78 | NOS1 (0.54) | NOS1DHFR | |
| SCHEMBL5013975 | 0.78 | NOS1 (0.61) | NOS1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| US-20150216167-A1 | SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES | HEINRICH HEINE UNIVERSITAT DUSSELDORF (DE) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | NOS1 4167/4885DHFR 1/4885 |
| US-20150216167-A1 | SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES | CBR3, GRHPR, PCK1 | NOS1 4480/4885DHFR 703/4885 |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | NOS1 4167/4885DHFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.